You are here


Submitted by kheredia on Thu, 10/17/2019 - 17:37

For a 60 years, scientists have deduced that medical therapy is not a generalized treatment. This is due to the widspread side effects in patients who undergo therapy, with treatment rarely ending in success. Undoubtedly, there was much to be discovered about the relationship between host genetics and response to treatment for diseases. However, it is this drawback that has lead to modern day’s focus on Personalized medicine (PM). Disease therapies are now fine-tuned and specialized, reducing the rate of failure to almost zero. Though this medical model is not necessarily new, technological and computational advances have allowed PM to increasingly gain attention within the last decade. Current research on personalized medicine has created opportunities for both the patient and healthcare providers in the pharmaceutical sector.

To add, the PM approach costs less, and is more efficient than the traditional medical care process. This is because of its ability to individualize, creating more space for the budget by reducing the large amounts spent on Clinical trials (CT) traditionalluy used with other techniques. PM focuses on the DNA of the patient to treat disease. There are new advances which will gain public’s understanding of the human body and expand the market. Scientists have been researching our genome and focusing on single nucleotide polymorphisms (SNPs) through the development of genetic analysis tests. These tests, or genetic kits made available to the public, are in the first stages of many.